KRAS mutations testing in colorectal carcinoma patients in Italy: from guidelines to external quality assessment
Articolo
Data di Pubblicazione:
2011
Abstract:
Background: Monoclonal antibodies directed against the epidermal growth factor receptor (EGFR) have been approved for
the treatment of patients with metastatic colorectal carcinoma (mCRC) that do not carry KRAS mutations. Therefore, KRAS
testing has become mandatory to chose the most appropriate therapy for these patients.
Methodology/Principal Findings: In order to guarantee the possibility for mCRC patients to receive an high quality KRAS
testing in every Italian region, the Italian Association of Medical Oncology (AIOM) and the Italian Society of Pathology and
Cytopathology -Italian division of the International Academy of Pathology (SIAPEC-IAP) started a program to improve KRAS
testing. AIOM and SIAPEC identified a large panel of Italian medical oncologists, pathologists and molecular biologists that
outlined guidelines for KRAS testing in mCRC patients. These guidelines include specific information on the target patient
population, the biological material for molecular analysis, the extraction of DNA, and the methods for the mutational
analysis that are summarized in this paper. Following the publication of the guidelines, the scientific societies started an
external quality assessment scheme for KRAS testing. Five CRC specimens with known KRAS mutation status were sent to
the 59 centers that participated to the program. The samples were validated by three referral laboratories. The participating
laboratories were allowed to use their own preferred method for DNA extraction and mutational analysis and were asked to
report the results within 4 weeks. The limit to pass the quality assessment was set at 100% of true responses. In the first
round, only two centers did not pass (3%). The two centers were offered to participate to a second round and both centers
failed again to pass.
Conclusions: The results of this first Italian quality assessment for KRAS testing suggest that KRAS mutational analysis is
performed with good quality in the majority of Italian centers.
Tipologia CRIS:
03A-Articolo su Rivista
Elenco autori:
Normanno N; Pinto C; Castiglione F; Bardelli A; Gambacorta M; Botti G; Nappi O; Siena S; Ciardiello F; Taddei G; Marchetti A
Link alla scheda completa:
Pubblicato in: